"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26202949.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1146.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Endocrine resistance leads to recurrence and death from breast cancer. Animal models of endocrine resistance enable preclinical identification of efficacious therapeutic combinations and further our understanding of resistance. This strategy provides new insights into optimally targeting interactions between estrogen receptor (ESR-1) activity and the cell cycle by CDK4/6 inhibitors. See related article by Wardell et al., p. 5121.
Medical subject headings
- Drug Resistance, Neoplasm
- Neoplasm Recurrence, Local